Startup Spotlight: Kernel’s non-invasive brain recording

By William Smith
Kernel is a Los Angeles, California-based startup developing non-invasive brain recording technology...

Kernel is a Los Angeles, California-based startup developing non-invasive brain recording technology.

The company’s neuroscience as a service (NaaS) platform is commercially available, enabling customers to access brain imaging devices remotely.

Its brain recording technologies are known as Flow and Flux. The latter detects magnetic fields generated by neural activity, while Flow measures blood flow as representative of neural activity.

It says its products overcome the limitations of current brain imaging hardware, which can be expensive, bulky or require surgery.

Kernel hopes to create an ecosystem for human improvement based on what it calls a “neurome”, analogous to a person’s genome.

Since its foundation in 2016, the company has raised a significant sum. Its latest Series C, which it said was its first outside funding round, saw the company raise $53mn from lead investor General Catalyst, alongside Tiny Blue Dot, Manta Ray Ventures, Khosla Ventures and Eldridge.

In a press release, the company’s CEO and founder Bryan Johnson said: “Mainframes became PCs and then smartphones. The $1B genome became the $1,000 genome. The brain and mind are next. 

“We live in a data-illuminated world, but the user manuals for our brains have no diagnostic or useful numbers, leaving us with no option but to describe and characterize cognition using hunches.” Johnson continued, “Imagine a cardiologist asking you how your heart is doing based upon your hunches, without cholesterol or blood pressure.

“If we can quantify thoughts and emotions, conscious and subconscious, a new era of understanding, wellness, and human improvement will emerge.”

The company said it would use the investment to accelerate on-demand access to its products, developing its technology further.

“The vision fueling Kernel is one of the most audacious imaginable.” said Quentin Clark, General Partner, General Catalyst. “But that ambition has a passionate and committed founder and team, and pragmatic engineering work to back it up. Kernel’s engineering accomplishments have the potential to enable more neuroscience progress in the next few years than has been accomplished in the last few decades.”

Share

Featured Articles

McKinsey: Women More Likely to die of Heart Attack Than Men

McKinsey Health Institute's Lucy Pérez says cardiovascular disease top killer of women yet physicians don't know their heart attack symptoms are different

Novo Nordisk Buys $1bn Cardior in CardioVascular Move

As Novo Nordisk expands into heart medicines, we profile the Danish pharma giant who in 1923 was the first to make insulin commercially available

Shoddy Chinese Syringes Sees BD Ramp-up Production

Becton Dickinson – a major supplier of syringes – said it has upped manufacturing in its US facilities after FDA warning on China-made products

AI Tool 'Picks up Early-stage Breast Cancers Doctors Missed'

Technology & AI

AstraZeneca Buys $2bn Fusion in Next-gen Cancer Drugs Move

Medical Devices & Pharma

Eli Lilly and Amazon Pharmacy Partner on Drugs Delivery

Digital Healthcare